Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Precision Biosciences Inc (NQ: DTIL ) 9.720 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Precision Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis August 09, 2024 From Precision BioSciences, Inc. Via Business Wire 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. Via InvestorPlace Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 01, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming August Investor Conferences July 31, 2024 From Precision BioSciences, Inc. Via Business Wire Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings) May 16, 2024 Via Benzinga Earnings Preview: Precision BioSciences March 26, 2024 Via Benzinga Precision BioSciences to Report Second Quarter Results on August 1, 2024 July 29, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit July 08, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces its Addition to the Russell Microcap® Index July 01, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025 June 27, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness June 20, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress June 05, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Participate in Upcoming June Investor Conferences May 30, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) May 17, 2024 From Precision BioSciences, Inc. Via Business Wire DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 DTIL stock results show that Precision BioSciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 13, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement May 08, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences to Report First Quarter Results on May 13, 2024 May 07, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency May 07, 2024 From Precision BioSciences Via Business Wire Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 May 01, 2024 From Precision BioSciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session April 17, 2024 Via Benzinga Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics April 16, 2024 From Precision BioSciences, Inc. Via Business Wire DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023 March 27, 2024 DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update March 27, 2024 From Precision BioSciences, Inc. Via Business Wire Earnings Scheduled For March 27, 2024 March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Via Benzinga Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 March 20, 2024 From Precision BioSciences, Inc. Via Business Wire Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy March 19, 2024 From Precision BioSciences Via Business Wire Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency March 06, 2024 From Precision BioSciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Friday's Intraday Session March 01, 2024 Via Benzinga Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 01, 2024 Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.